Next-Gen GLP-1 Pipeline 2026: What's in Trials, Timelines, and Mechanisms

Last updated: June 2026

Medical disclaimer: This article is for informational purposes only and is not medical advice. Most drugs below are investigational and not FDA-approved. Trial timelines change. Do not start, stop, or change treatment based on this. Consult your doctor.

The first wave of GLP-1 drugs was simple. One hormone, one shot, one effect. The next wave is not.

By mid-2026 the field has split into oral pills, multi-receptor combos, and amylin drugs that may match the old shots with fewer side effects. This is the full map of what's in trials, when it might arrive, and how each one works. We update it as new data lands.

What's driving the next wave of GLP-1 drugs?

The push is to do more than one thing at once, and to do it without a needle. Single-hormone drugs like semaglutide proved the idea. Now drugmakers are stacking hormones and switching to pills.

The first GLP-1 drugs copied one gut hormone. That hormone tells your brain you're full and slows your stomach. It works, but a single target has limits. Most people plateau somewhere around 15% weight loss, and a lot of them can't tolerate the nausea.

So companies started combining receptors. Add GIP and you get tirzepatide. Add glucagon on top and you get a triple agonist. Each added target can squeeze out more weight loss, raise calorie burn, or protect the liver.

The other big shift is the route. Shots work, but many people hate needles and pills are easier to make and ship at scale. A daily tablet also opens the door to far more patients worldwide. That's why the oral versus injectable question now sits at the center of the field.

There's a third driver: tolerability. The amylin drugs aren't chasing the biggest number. They're chasing a drug people can actually stay on. If half of patients quit a powerful drug because of nausea, a gentler drug with slightly less weight loss may win in the real world.

A fourth driver is money and reach. Obesity affects more than a billion people worldwide, and injections are hard to scale to that many patients. Pills, cheaper manufacturing, and longer dosing intervals all aim at the same goal: treating far more people than the first GLP-1 shots ever could. That commercial race is part of why so many drugs are in trials at once.

Put together, these forces explain the whole landscape below. More receptors for more effect. Pills for more reach. Amylin for better tolerability. And a handful of giant drugmakers racing to own the next standard of care.

The full next-gen GLP-1 pipeline at a glance

This is the master map, the heart of this page. It pulls together every major next-gen GLP-1 and GLP-1-adjacent drug in one place: who makes it, how it works, its lead trial, where it stands with regulators, when it might arrive, and the best weight loss reported so far.

Status is current as of June 2026 and changes fast, so always check with your doctor and the latest company releases before drawing conclusions.

Drug	Maker	Mechanism	Top trial	Phase / status	Est. U.S. timeline	Top-line weight loss
Orforglipron (Foundayo)	Eli Lilly	Oral GLP-1 agonist	ATTAIN-1	FDA-approved (Apr 1, 2026)	Available now	Up to 12.4% at 72 wks
Oral semaglutide 25mg (Wegovy pill)	Novo Nordisk	Oral GLP-1 agonist	OASIS 4	FDA-approved (Dec 22, 2025)	Available now	16.6% (per protocol)
Retatrutide (LY3437943)	Eli Lilly	GLP-1 / GIP / glucagon triple	TRIUMPH-1	Phase 3, investigational	Filing late 2026; approval ~2027–28	28.3% at 80 wks (12mg)
CagriSema	Novo Nordisk	Amylin (cagrilintide) + GLP-1	REDEFINE 1	Phase 3, FDA review (filed Dec 2025)	Decision possible 2026	20.4% at 68 wks
Survodutide (BI 456906)	Boehringer / Zealand	GLP-1 / glucagon dual	SYNCHRONIZE-1	Phase 3, investigational	Filing ~2026–27	16.6% at 76 wks
Mazdutide	Innovent / Eli Lilly	GLP-1 / glucagon dual	GLORY-2	Approved in China (2025); investigational in U.S.	China only for now	Up to 20.1% (9mg)
MariTide (maridebart cafraglutide)	Amgen	GLP-1 agonist / GIP antagonist	MARITIME	Phase 3, investigational	Phase 3 readouts ~2026–27	~20% at 52 wks (Phase 2)
Amycretin	Novo Nordisk	Amylin + GLP-1 (oral + injectable)	Phase 2 T2D	Phase 2 done; Phase 3 starting 2026	Years out	Up to 11.9% (T2D, Phase 2)
Petrelintide	Zealand / Roche	Amylin analog	ZUPREME-1	Phase 2 done; Phase 3 starting H2 2026	Years out	10.7% at 42 wks (Phase 2)

Two pills are now real products you can fill at a pharmacy. The rest are still in trials, and most of the biggest numbers belong to drugs you can't buy yet.

A few notes on reading this table. "Top-line weight loss" is the best result reported so far, not what an average person should expect. Trial patients are screened, supported, and pushed to the highest tolerated dose. Real-world numbers tend to run lower. Phase 2 results, like petrelintide's, can also shrink in the larger Phase 3 trials that follow.

The lead trials each carry a ClinicalTrials.gov identifier so you can read the protocol yourself. Retatrutide's pivotal obesity study, TRIUMPH-1, is NCT05929066, and it enrolled 2,339 patients (Eli Lilly, 2026). CagriSema's REDEFINE 1 is registered as NCT05567796 and enrolled 3,417 adults (NEJM, 2025). MariTide's obesity sleep-apnea study runs under NCT07225686 (ClinicalTrials.gov, 2026). You can look up any of these on ClinicalTrials.gov for enrollment, doses, and endpoints.

A word on the makers. Two companies dominate. Eli Lilly owns orforglipron, retatrutide, and a slice of mazdutide. Novo Nordisk owns the Wegovy pill, CagriSema, and amycretin. The challengers are Boehringer with Zealand on survodutide, Amgen on MariTide, and Roche teaming with Zealand on petrelintide. That's the competitive map in one paragraph.

Which mechanisms are being combined and why?

Each hormone target adds a different job: appetite, blood sugar, fat burning, or fullness. Combining them is how the new drugs beat the old ones on paper.

Here's what each receptor brings to the table.

Receptor	What it does	Found in
GLP-1	Cuts appetite, slows stomach, lowers blood sugar	All drugs here
GIP	Adds blood sugar control; may ease nausea (agonist)	Tirzepatide, retatrutide
GIP (antagonist)	Blocking it may also drive weight loss	MariTide
Glucagon	Raises energy burn, helps the liver burn fat	Retatrutide, survodutide, mazdutide
Amylin	Boosts fullness with gentler GI side effects	CagriSema, amycretin, petrelintide

The glucagon angle is the most counterintuitive. Glucagon usually raises blood sugar, which sounds wrong for a metabolic drug. But pair it with GLP-1 and the GLP-1 keeps sugar in check while glucagon ramps up calorie burn and pushes the liver to burn its own fat. That combo is why survodutide is being tested in liver disease, not just obesity (Boehringer Ingelheim, 2026).

The GIP target gets used in two opposite ways, which confuses people. Tirzepatide and retatrutide turn GIP on. Amgen's MariTide blocks it. Both approaches drive weight loss in trials, and researchers are still working out why blocking and activating the same receptor can both help (Amgen, 2026).

Amylin is the gentler path. Amylin is a hormone your pancreas releases alongside insulin, and it signals fullness through a different route than GLP-1. Drugs that mimic it aim for solid weight loss with far less nausea and vomiting.

In its Phase 2 ZUPREME-1 trial, petrelintide caused no vomiting at the top effective dose and no GI-related dropouts (Zealand Pharma, 2026). That tolerability is the headline, not the 10.7% weight loss.

CagriSema takes a different angle. It bolts an amylin drug, cagrilintide, onto semaglutide to get both effects in one weekly shot. Amycretin folds both jobs into a single molecule that comes as a pill or an injection. Three roads to the same idea: combine appetite signals to lose more weight while keeping the stomach calmer.

What's approved vs investigational right now?

Only the oral pills are approved. Everything else is still in trials. This is the line that matters most for anyone reading the headlines.

On April 1, 2026, the FDA approved orforglipron as Foundayo, the first oral GLP-1 pill you can take any time of day without food or water rules (Eli Lilly, 2026). It's a daily tablet for adults with obesity, or overweight with a weight-related condition.

Before that, on December 22, 2025, the FDA approved the Wegovy pill (oral semaglutide 25mg), the first oral GLP-1 cleared for weight management (Applied Clinical Trials, 2026). It came out of the OASIS trial program and also carries a heart-risk-reduction use based on the SELECT trial. So as of mid-2026, the U.S. has two approved oral GLP-1 pills, both daily tablets.

Everything else is investigational in the U.S. Retatrutide, CagriSema, survodutide, MariTide, amycretin, and petrelintide are all still in trials and not approved. CagriSema is the closest behind the pills; Novo Nordisk submitted it to the FDA in December 2025 (Novo Nordisk, 2026). It's an injection, not a pill, so it won't compete with the oral drugs on convenience.

Why does this matter so much? Because "in the pipeline" gets thrown around loosely. A drug in Phase 2 and a drug under FDA review are years apart. The chart below in the timelines section sorts that out. The short version: don't expect to fill a prescription for retatrutide, survodutide, MariTide, amycretin, or petrelintide in 2026.

Mazdutide is a special case. China's NMPA approved it for weight management in June 2025, the world's first dual glucagon/GLP-1 drug cleared for weight loss, but it is not approved in the U.S. (Fierce Pharma, 2025). Lilly licenses it in China through Innovent. Whether it ever files in the U.S. is an open question, since Lilly already has orforglipron and retatrutide in its own lineup.

So the practical takeaway is simple. If you want a next-gen drug today, your choices are the two oral pills. Everyone else is waiting on trial data and FDA review.

What are the expected approval timelines?

The pills are here. The big combo shots are mostly 2027 or later. Dates below are estimates and shift with trial data and FDA review.

Drug	Status	Likely next milestone
Foundayo (orforglipron)	Approved Apr 2026	On the market now
Wegovy pill (oral sema 25mg)	Approved Dec 2025	On the market now
CagriSema	Under FDA review	Decision possible in 2026
Retatrutide	Phase 3	Filing late 2026 / early 2027; approval ~2027–28
Survodutide	Phase 3	Filing ~2026–27
MariTide	Phase 3 (MARITIME)	Readouts ~2026–27
Amycretin	Phase 3 starting 2026	Years out
Petrelintide	Phase 3 starting H2 2026	Years out

For retatrutide, Lilly reported positive TRIUMPH-1 results on May 21, 2026, but had not yet filed with the FDA by June 2026 (Eli Lilly, 2026). The company is waiting on more TRIUMPH readouts, including diabetes and cardiovascular data, before submitting. A realistic FDA decision lands in 2027 or 2028. Our full retatrutide evidence review tracks each TRIUMPH readout as it lands.

Survodutide is moving too. Boehringer reported positive Phase 3 SYNCHRONIZE-1 obesity data and SYNCHRONIZE-MASLD liver data at the ADA 2026 meeting, which sets up a filing in the next year or two (Boehringer Ingelheim, 2026). The amylin drugs, amycretin and petrelintide, are the furthest out. Both are only now starting Phase 3, so any approval is several years away.

One caution on all these dates. A filing is not an approval, and a positive Phase 3 is not a filing. The FDA can ask for more data, and companies can delay. Treat every future date here as a best guess, not a promise.

How much weight loss might the next generation deliver?

The triple agonist retatrutide leads with 28.3%, and the amylin drugs trail but win on tolerability. Bigger numbers usually come with more side effects, so the right pick depends on the person.

Drug	Trial	Best weight loss	Notes
Retatrutide	TRIUMPH-1 (Phase 3)	28.3% at 80 wks (12mg)	Up to 30.3% at 104 wks in higher-BMI group
CagriSema	REDEFINE 1 (Phase 3)	20.4% at 68 wks	23% lost 30%+ of body weight
Mazdutide	GLORY-2 (Phase 3, China)	20.1% (9mg)	Approved in China
MariTide	Phase 2	~20% at 52 wks	No plateau seen at 52 wks
Survodutide	SYNCHRONIZE-1 (Phase 3)	16.6% at 76 wks	Also normalized liver fat in MASLD
Oral semaglutide 25mg	OASIS 4	16.6% (per protocol)	Approved Dec 2025
Foundayo	ATTAIN-1	Up to 12.4% at 72 wks	Approved, daily pill
Amycretin	Phase 2 (T2D)	11.9% (injectable)	No plateau at week 36
Petrelintide	ZUPREME-1 (Phase 2)	10.7% at 42 wks	Placebo-like tolerability

Retatrutide's 28.3% is the largest weight loss ever published in a Phase 3 obesity trial, beating tirzepatide's SURMOUNT-1 by roughly 5.8 points (AJMC, 2026). In a subgroup with higher starting BMI who stayed on the drug, the figure reached 30.3% at 104 weeks. For a head-to-head look at the leaders, see our CagriSema vs tirzepatide vs retatrutide comparison.

CagriSema's story is messier. REDEFINE 1 showed a strong 20.4% mean loss, but the company had hoped for 25% and an open-label head-to-head against tirzepatide later missed its primary endpoint (NEJM, 2025). It still beat placebo by a wide margin. The lesson is that "missing a target" and "not working" are very different things, and headlines often blur them.

The amylin drugs land lower on weight loss but may win where it counts for staying on the drug: side effects. Petrelintide hit 10.7% with placebo-like tolerability, and amycretin showed 11.9% in diabetes patients with no plateau by week 36 (Novo Nordisk, 2025). That trade-off could matter more than the raw number for a lot of people.

Survodutide and mazdutide sit in the middle, around 16% to 20%. Survodutide's edge isn't the scale number, though. Its glucagon arm normalized liver fat in six of ten patients with fatty liver disease, which points to a use beyond weight loss (Boehringer Ingelheim, 2026).

One last caveat on these numbers. Cross-trial comparisons are rough. Each study used different patients, doses, and lengths, so a one-point gap between drugs may not mean much. The only clean comparisons come from head-to-head trials, and there are still very few of those.

What are the open questions and risks?

The hard questions are about safety over years, muscle loss, cost, and whether the weight stays off. None of these are fully answered yet, and the newest drugs have the least long-term data.

Long-term safety is the biggest unknown. Phase 3 trials run for one to two years. People may take these drugs for decades, and we simply don't have decade-long data on the newest combos. Adding a third receptor like glucagon also adds new ways the drug can affect the heart, liver, and blood sugar that need years to fully map.

Muscle loss is a real worry. A big chunk of the weight lost on any GLP-1 drug is lean mass, not just fat. That matters most for older adults, where muscle loss can mean weaker bones and more falls. Whether the multi-receptor drugs make this better or worse is still being studied, and it's one reason exercise and protein intake stay important on these drugs.

Cost and access are not solved. Foundayo starts at $149 a month for self-pay at the lowest dose, and the injectables can run far higher without insurance (Eli Lilly, 2026). Insurance coverage for obesity drugs is patchy, and the newest agents will likely launch at premium prices. For a full picture of options, see our overview of GLP-1 medications.

Durability is the last big question. Most people who stop these drugs regain much of the weight. The newer agents have not shown they break that pattern, so for now the working assumption is long-term, possibly lifelong, use. That makes the safety and cost questions above even more important.

Tolerability ties it all together. The strongest drug helps no one if people quit it. That's the real test the next generation faces, and it's why the gentler amylin drugs are worth watching even though their numbers look smaller on paper.

Frequently Asked Questions

Is any next-gen GLP-1 pill actually approved yet?

Yes. Two oral GLP-1 pills are FDA-approved: the Wegovy pill (oral semaglutide 25mg, approved December 2025) and Foundayo (orforglipron, approved April 1, 2026). Both are taken by mouth for weight management in adults with obesity or overweight with a related condition.

When will retatrutide be available?

Retatrutide is still investigational as of mid-2026. Lilly reported strong Phase 3 TRIUMPH-1 results in May 2026 but had not filed with the FDA yet. A filing is expected in late 2026 or early 2027, once more TRIUMPH data is in hand, with a possible approval in 2027 or 2028. Nothing is guaranteed, and avoid any source selling "retatrutide" before approval, since it isn't a legal product yet.

Which next-gen drug causes the most weight loss?

In published Phase 3 data, retatrutide leads with 28.3% average weight loss at 80 weeks on the 12mg dose, and up to 30.3% in some higher-BMI participants. CagriSema and mazdutide both land near 20%. Higher weight loss often comes with more side effects.

What's the difference between a dual and a triple agonist?

A dual agonist hits two hormone receptors, like survodutide (GLP-1 and glucagon) or tirzepatide (GLP-1 and GIP). A triple agonist hits three. Retatrutide is the lead triple agonist, targeting GLP-1, GIP, and glucagon at once, which appears to drive its larger weight loss.

Are amylin drugs like petrelintide better than GLP-1 drugs?

Not on weight loss alone. Amylin drugs like petrelintide and CagriSema's amylin component aim for a gentler side-effect profile, especially less nausea and vomiting. In Phase 2, petrelintide lost about 10.7% with placebo-like tolerability. The appeal is staying on the drug, not the biggest number.

Related Reading

• Retatrutide: complete evidence review
• Orforglipron: complete evidence review
• CagriSema vs tirzepatide vs retatrutide

-- The GLP-1 Daily Team